SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending following a Bloomberg report confirming that its highly anticipated foldable iPhone remains on track for a September release, helping to ease investor concerns regarding earlier rumors of engineering delays. While the stock faced recent volatility linked to legal patent disputes in China and broader geopolitical tension, the community is currently focused on the company's technical recovery and potential production momentum.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is seeing significant market activity as a massive short squeeze unfolds, fueled by over 65% of the free float being shorted and intense retail interest. While some analysts have issued downgrades based on fundamental concerns like high debt and valuation, the community is actively debating the potential for a parabolic move similar to previous squeeze cycles.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is surging after securing a major production order from a lead hyperscale customer for its ultra-high-power Sonoma testing platforms, signaling significant momentum in the AI chip infrastructure market. The community is actively discussing this as a major validation of the company's technology, with many traders viewing the news as a critical turning point that could drive sustained growth through 2027.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is trending following a solid earnings report that exceeded top-line expectations and included upbeat fiscal year guidance, helping to soothe investor anxieties about potential AI-driven disruption. The community is actively debating the company's valuation against its long-term cybersecurity dominance, while many traders continue to focus on how geopolitical tensions and the rapid adoption of AI will drive continued enterprise demand for the platform.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axon Enterprise is facing significant selling pressure as investors grapple with valuation concerns and technical weakness, despite the company launching new AI-powered tools during its highly anticipated Axon Week event. The community remains deeply divided, with some traders actively scalp-trading the volatility or scaling into long-term positions, while others express frustration over the sharp decline and the company's high price-to-earnings multiple.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz Global Holdings Inc

Hertz is currently experiencing significant retail and institutional interest driven by its high short interest and technical setup, with many traders anticipating a short squeeze ahead of upcoming earnings. The community is actively tracking option flow and potential catalysts, such as increased travel demand, while monitoring closely for any moves from major shareholders like Bill Ackman.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as investors digest a mix of positive Phase 3 oncology trial results and ongoing uncertainty surrounding revenue from COVID-related products. The community is actively debating the stock's long-term value against its sluggish price action, with many traders focused on the high dividend yield and speculation about potential M&A activity within the oncology sector.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is rallying amid intensifying geopolitical tensions as traders closely monitor a looming deadline for potential military escalation in the Middle East. Market participants are actively debating whether the current price action reflects genuine supply disruption fears or speculative positioning ahead of a possible diplomatic resolution or further military action.

Levi Strauss & Co. engages in the design, marketing, and sale of apparel products. The firm offers jeans, casual and dress pants, tops, shorts, skirts, jackets, footwear, and related accessories. It operates through the following geographical segments: Americas, Europe, and Asia. The company was founded by Levi Strauss in 1853 and is headquartered in San Francisco, CA.

Levi Strauss & Co. - Ordinary Shares - Class A

Levi Strauss & Co. - Ordinary Shares Cls A

Levi Strauss is trending as investors digest the impact of tariff uncertainty on supply chains ahead of quarterly earnings, with the market closely monitoring management's guidance on margin pressures versus direct-to-consumer growth. The community remains divided, weighing the potential for a relief rally against concerns that near-term cost headwinds could force a downward revision of future profit expectations.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as the community rallies around its unique origin story as a parody of the original Bitcoin, now positioned as a long-standing cultural phenomenon in the meme coin space. Investors are actively debating its longevity and potential for widespread adoption, with many pointing to its history dating back over a decade as a differentiator in a market saturated with short-lived projects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bicara Therapeutics (NASDAQ:BCAX) Sets New 12-Month High - Here's Why

Bicara Therapeutics (NASDAQ:BCAX) Sets New 52-Week High - Time to Buy...

HC Wainwright Has Bullish Estimate for BCAX Q1 Earnings

Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Analysts at HC Wainwright boosted their Q1 2026 earnings per share estimates for Bicara Therapeutics in a research report issued on Tuesday...

Bicara Therapeutics (NASDAQ:BCAX) Hits New 1-Year High Following Analyst Upgrade

Bicara Therapeutics (NASDAQ:BCAX) Sets New 12-Month High on Analyst Upgrade...

Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 54.9% in Bicara Therapeutics Inc. (BCAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year?

Here is how CareCloud, Inc. (CCLD) and Bicara Therapeutics Inc. (BCAX) have performed compared to their sector so far this year.

Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $16.00 at The Goldman Sachs Group

The Goldman Sachs Group increased their target price on Bicara Therapeutics from $14.00 to $16.00 and gave the company a "neutral" rating in a research note on Tuesday...

Bicara Therapeutics (NASDAQ:BCAX) Given "Outperform" Rating at Wedbush

Wedbush reiterated an "outperform" rating and set a $30.00 price objective on shares of Bicara Therapeutics in a research report on Tuesday...

Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $16.00 at Wells Fargo & Company

Wells Fargo & Company upped their price target on shares of Bicara Therapeutics from $11.00 to $16.00 and gave the stock an "equal weight" rating in a research report on Tuesday...

Citizens Jmp Reiterates "Market Outperform" Rating for Bicara Therapeutics (NASDAQ:BCAX)

Citizens Jmp restated a "market outperform" rating and issued a $31.00 price objective on shares of Bicara Therapeutics in a research note on Tuesday...

Bicara Therapeutics To Rally Around 121%? Here Are 10 Top Analyst Forecasts For Tuesday

Top analysts changed outlook on top names. See all changes on analyst ratings page. BTIG & HCW cut price targets, Needham & BMO raised, Baird bcut.read more...

Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.

Current Price	$21.17
Prev Close	$20.85
Open	$21.02
Dividend Yield	0.00%
50-Day Moving Average	$17.49
Beta	1.73
Avg. Volume	610,609.08
PE Ratio	-8.27

52-Week High	$21.63
52-Week Low	$7.80
Market Capitalization	$1.36B
EPS (Annual)	-$2.52
Price to Book	2.94
Revenue Per Employee	$0.00

BCAX
Bicara Therapeutics

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BCAX News

BCAXBicara Therapeutics